Liver enhancement during hepatobiliary phase after Gd-BOPTA administration: correlation with liver and renal function.
Bilirubin
Gadobenic acid
Liver
Magnetic resonance imaging
Renal insufficiency
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
10
04
2020
accepted:
10
09
2020
revised:
25
06
2020
pubmed:
2
10
2020
medline:
15
4
2021
entrez:
1
10
2020
Statut:
ppublish
Résumé
To assess the influence of liver and renal function on liver relative enhancement during hepatobiliary phase MRI after Gd-BOPTA administration. In this IRB-approved retrospective cohort study, we included 326 patients who underwent Gd-BOPTA-enhanced 1.5T liver MRI, including hepatobiliary phase (HBP) acquired 90-150 min after injection, in two centres between Jan 2016 and Dec 2019. Liver signal intensity was measured on native and HBP phases and normalized to paraspinal muscles. Liver normalized relative enhancement (NRE) in HBP was calculated and compared with eGFR, total serum bilirubin and HBP acquisition delay by means of Spearman r correlation test and Mann-Whitney U test. 221/326 patients received 0.05 mmol/Kg Gd-BOPTA (group A), whereas 105/326 received 0.1 mmol/Kg (group B). Liver NRE in HBP was significantly higher in group B than in group A (0.55vs.0.33, p < 0.0001). In both groups, liver NRE in HBP had a negative correlation with total serum bilirubin level (r = - 0.32, p < 0.0001, group A; r = - 0.36, p = 0.0002, group B). Patients with total bilirubin > 1.2 mg/dl showed significantly lower NRE in HBP compared with those with total bilirubin ≤ 1.2 mg/dl (p < 0.0001, group A; p = 0.04, group B). Patients with impaired liver function in group B showed a NRE during HBP comparable with those with normal liver function in group A. No statistically significant correlation between liver NRE and eGFR or acquisition delay was observed. The degree of liver enhancement during HBP is not correlated with eGFR or acquisition delay, but it is significantly reduced in patients with impaired liver function. 0.1 mmol/kg Gd-BOPTA dose might be useful in patients with total serum bilirubin > 1.2 mg/dl. • The degree of liver enhancement during hepatobiliary phase after Gd-BOPTA administration has a negative correlation with total serum bilirubin level (r = - 0.32, p < 0.0001). • The degree of liver enhancement during HBP after Gd-BOPTA administration is not significantly correlated with renal function and acquisition delay (comprised between 90 and 150 min after contrast injection). • 0.1 mmol/Kg Gd-BOPTA dose might be preferable in patients with increased total serum bilirubin levels.
Identifiants
pubmed: 33000303
doi: 10.1007/s00330-020-07279-6
pii: 10.1007/s00330-020-07279-6
doi:
Substances chimiques
Contrast Media
0
Organometallic Compounds
0
gadobenic acid
15G12L5X8K
Meglumine
6HG8UB2MUY
Gadolinium DTPA
K2I13DR72L
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2490-2496Références
de Haen C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 23(Suppl 1):S161–S168
doi: 10.1097/00004728-199911001-00021
Bonatti M, Valletta R, Zamboni GA et al (2019) Ascites relative enhancement during hepatobiliary phase after Gd-BOPTA administration: a new promising tool for characterising abdominal free fluid of unknown origin. Eur Radiol 29:2830–2836
doi: 10.1007/s00330-018-5932-y
Cavagna FM, Maggioni F, Castelli PM et al (1997) Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796
doi: 10.1097/00004424-199712000-00009
Cavagna FM, Marzola P, Dapra M et al (1994) Binding of gadobenate dimeglumine to proteins extravasated into interstitial space enhances conspicuity of reperfused infarcts. Invest Radiol 29(Suppl 2):S50–S53
doi: 10.1097/00004424-199406001-00018
Ciolina M, Di Martino M, Bruno O, Pommier R, Vilgrain V, Ronot M (2018) Peritoneal and pleural fluids may appear hyperintense on hepatobiliary phase using hepatobiliary MR contrast agents. Eur Radiol. https://doi.org/10.1007/s00330-017-5261-6
de Haen C, La Ferla R, Maggioni F (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals. J Comput Assist Tomogr 23(Suppl 1):S169–S179
doi: 10.1097/00004728-199911001-00022
Daire JL, Leporq B, Vilgrain V, Van Beers BE, Schmidt S, Pastor CM (2017) Liver perfusion modifies Gd-DTPA and Gd-BOPTA hepatocyte concentrations through transfer clearances across sinusoidal membranes. Eur J Drug Metab Pharmacokinet 42:657–667
doi: 10.1007/s13318-016-0382-x
Nural MS, Gokce E, Danaci M, Bayrak IK, Diren HB (2008) Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose. Eur J Radiol 66:65–74
doi: 10.1016/j.ejrad.2007.04.022
Pena CS, Saini S, Baron RL et al (2001) Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial. Korean J Radiol 2:210–215
doi: 10.3348/kjr.2001.2.4.210
de Campos RO, Heredia V, Ramalho M et al (2011) Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations. AJR Am J Roentgenol 196:545–552
doi: 10.2214/AJR.10.4500
Ramalho M, AlObaidy M, Busireddy KK, Altun E, Liu B, Semelka RC (2015) Quantitative and qualitative comparison of 0.025 mmol/kg gadobenate dimeglumine for abdominal MRI at 1.5T and 3T MRI in patients with low estimated glomerular filtration rate. Eur J Radiol 84:26–32
doi: 10.1016/j.ejrad.2014.10.016
Kirchin MA, Lorusso V, Pirovano G (2015) Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance((R))) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? Br J Radiol 88:20140526
doi: 10.1259/bjr.20140526
Swan SK, Lambrecht LJ, Townsend R et al (1999) Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 34:443–448
doi: 10.1097/00004424-199907000-00001
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
doi: 10.7326/0003-4819-150-9-200905050-00006
Lachin JM (1981) Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 2:93–113
doi: 10.1016/0197-2456(81)90001-5
Zhao X, Huang M, Zhu Q, Wang T, Liu Q (2015) The relationship between liver function and liver parenchymal contrast enhancement on Gd-BOPTA-enhanced MR imaging in the hepatocyte phase. Magn Reson Imaging 33:768–773
doi: 10.1016/j.mri.2015.03.006
Schima W, Saini S, Petersein J et al (1999) MR imaging of the liver with Gd-BOPTA: quantitative analysis of T1-weighted images at two different doses. J Magn Reson Imaging 10:80–83
doi: 10.1002/(SICI)1522-2586(199907)10:1<80::AID-JMRI11>3.0.CO;2-S
Jeong WK, Byun JH, Lee SS et al (2011) Gadobenate dimeglumine-enhanced liver MR imaging in cirrhotic patients: quantitative and qualitative comparison of 1-hour and 3-hour delayed images. J Magn Reson Imaging 33:889–897
doi: 10.1002/jmri.22492
de Haen C, Lorusso V, Luzzani F, Tirone P (1995) Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol 2:232–238
doi: 10.1016/S1076-6332(05)80171-0
Kim H, Kim MJ, Park MS et al (2010) Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging. J Comput Assist Tomogr 34:113–120
doi: 10.1097/RCT.0b013e3181aacd6b
Manfredi R, Maresca G, Baron RL et al (1998) Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 8:862–867
doi: 10.1002/jmri.1880080416